Latest Articles

Publication Date
Emerging roles and therapeutic potential of tRNA-Derived small RNAs in reproductive system diseases: a review.

tRNA-derived small RNAs (tsRNAs) are a class of non-coding RNAs(ncRNAs) generated from precursor or mature tRNAs under stress conditions, such as starvation, hypoxia, or oxidative stress. They are broadly classified …

Published: Dec. 3, 2025, midnight
Best Walmart Cyber Monday 2025 deals: Legos, Dyson vacuums, AirPods discounts - Mashable

Best Walmart Cyber Monday 2025 deals: Legos, Dyson vacuums, AirPods discounts Mashable

Published: Dec. 2, 2025, 9:20 p.m.
Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia - Business Wire

Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia Business Wire

Published: Dec. 2, 2025, 1:05 p.m.
Bayer (BAYRY) starts SUNFLOWER Phase III Mirena trial for nonatypical endometrial hyperplasia - Stock Titan

Bayer (BAYRY) starts SUNFLOWER Phase III Mirena trial for nonatypical endometrial hyperplasia Stock Titan

Published: Dec. 2, 2025, 1:05 p.m.
Bayer starts phase III study with Mirena for treatment of nonatypical endometrial hyperplasia - MarketScreener

Bayer starts phase III study with Mirena for treatment of nonatypical endometrial hyperplasia MarketScreener

Published: Dec. 2, 2025, 7:36 a.m.
Bayer starts new phase III study with Mirena for the treatment of nonatypical endometrial hyperplasia - MarketScreener

Bayer starts new phase III study with Mirena for the treatment of nonatypical endometrial hyperplasia MarketScreener

Published: Dec. 2, 2025, 7:36 a.m.
Bayer starts Phase III study with long-acting reversible intrauterine system for treatment of nonatypical endometrial hyperplasia - Bayer

Bayer starts Phase III study with long-acting reversible intrauterine system for treatment of nonatypical endometrial hyperplasia Bayer

Published: Dec. 2, 2025, 7:30 a.m.
Pain, emotional distress, and fear of recurrence or progression in people with endometriosis: a network approach.

Pain is a common debilitating symptom reported in people with endometriosis. Yet, we do not have a good understanding of factors that may contribute to higher pain and worse psychosocial …

Published: Dec. 2, 2025, midnight
The pelvic pain bias assessment: a new assessment of interpretation bias specific to pelvic pain.

Pelvic pain is a common and often debilitating experience with limited treatment options. Improving understanding of the psychosocial mechanisms involved in pelvic pain experiences will enhance the efficacy of pain …

Published: Dec. 2, 2025, midnight
Cartherics appoints Dr Ian Nisbet as CEO as the company accelerates toward clinical trials - BiotechDispatch

Cartherics appoints Dr Ian Nisbet as CEO as the company accelerates toward clinical trials BiotechDispatch

Published: Dec. 1, 2025, 11:34 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!